Status not kept up to date
A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)
NCT01590355 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated 8 March 2023
- What is being tested
- Radiotherapy; Transoral Robotic Surgery + Neck Dissection
- For
- Early-Stage Squamous Cell Carcinoma of the Oropharynx
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 68 people. The full rules are on the registry page.
- Where
- Australia, Canada (6 sites)
- When
- Starts or started June 2012, ends Sept 2023. Registered 2 May 2012.
- Results
- None posted yet.
In the researchers' words
The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx is radiation therapy. Some patients require chemotherapy with the radiation, and some patients require surgery if the tumour or lymph nodes have not responded after radiation. This study will compare radiation therapy with a new surgical treatment called transoral robotic surgery (TORS). TORS is a new surgical approach using a robot to assist the surgeon in removing the tumour, potentially with fewer side effects than older surgical techniques.
Sites
- Royal Adelaide HospitalAdelaide, Australia
- British Columbia Cancer AgencyVancouver, British Columbia, Canada
- London Regional Cancer Program of the Lawson Health Research InstituteLondon, Ontario, Canada
- The Ottawa Hospital Cancer CentreOttawa, Ontario, Canada
- University Health NetworkToronto, Ontario, Canada
- Jewish General HospitalMontreal, Quebec, Canada